BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved
'Unequivocal Benefit' Unveiled At ESC
Executive Summary
The full dataset from the closely-watched study demonstrated that Jardiance showed a 21% reduction in the risk of cardiovascular death or hospitalization for HFpEF compared with placebo, a significantly greater benefit than seen with the only approved drug for the indication, Novartis's Entresto.
You may also be interested in...
Novo Nordisk STEPs Into Heart Failure
The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.
BI/Lilly’s Jardiance To Face Off With AstraZeneca’s Farxiga In CKD After EU Nod
The SGLT2 inhibitor has won European approval for the treatment of chronic kidney disease and while rival AstraZeneca’s Farxiga has had a two-year head start in the space, Boehringer and Lilly could come out on top given Jardiance’s stronger sales records to date.
Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure
Treatment with Farxiga led to an 18% reduction in a composite endpoint comprising cardiovascular death or worsening heart failure, putting it in the same ballpark as Boehringer Ingelheim and Eli Lilly's Jardiance and its 21% reduction shown in the EMPEROR-Preserved trial last year.